News
-
XARELTO (rivaroxaban) Demonstrates Comparable Efficacy To Standard Of Care For The Treatment And Secondary Prevention Of Venous Blood Clots In Patients With Symptomatic Pulmonary Embolism In Pivotal Phase 3 Study
3/27/2012
Janssen Research & Development, LLC, (Janssen), announced results of the EINSTEIN-PE study showing that the oral anticoagulant XARELTO (rivaroxaban) was comparable to today’s standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary venous blood clot (known as venous thromboembolism or VTE).
-
Ampio Announces Positive Preliminary Update On The Optina™ Clinical Trial To Treat Diabetic Macular Edema And Decision To Conclude The Study Ahead Of Schedule
3/20/2012
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane™ completed two phase III studies, Ampion™-completed proof of concept studies and Optina™), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina™ trial for diabetic macular edema.
-
Grünenthal Selects BioClinica OnPoint Clinical Trial Management System
3/12/2012
BioClinica, Inc., a global provider of clinical trial management solutions, recently announced that Grünenthal GmbH has signed a global license agreement for BioClinica OnPoint CTMS to support its ongoing clinical trials.
-
Roche´s MagNA Pure LC 2.0 System For Monitoring DNA In Therapeutic Proteins And Monoclonal Antibody Drugs
3/2/2012
To ensure product safety, clearance of host-cell DNA is essential when manufacturing therapeutic proteins and monoclonal antibody (mAB) drugs.
-
Premier Research Expands Salt Lake City And Phoenix Testing Facilities Adding 50% Capacity
2/22/2012
Premier Research Group Limited announces the opening of new state-of-the-art clinical research facilities located in Phoenix and Salt Lake City, increasing their testing facilities capacity by 50%.
-
Salk Researchers Find New Drug Target For Lung Cancer
2/21/2012
Drugs targeting an enzyme involved in inflammation might offer a new avenue for treating certain lung cancers, according to a new study by scientists at the Salk Institute for Biological Studies.
-
Roche’s xCELLigence Cardio Instrument Used To Detect Beating Rhythm And Proarrhythmic Effects Of Compounds In Stem Cell-Derived Cardiomyocytes
2/10/2012
In an effort to improve preclinical cardiotoxicity assays, reduce drug testing attrition rates, and ensure drug safety, collaborating scientists at the University Medical Center Utrecht in the Netherlands, and Bioscience Department of AstraZeneca R&D, Mölndal, Sweden, have tested Roche’s xCELLigence Cardio Instrument.
-
ERT And UCLA Initiate Innovative Pilot Program For Chronically Ill Patients
2/9/2012
ERT, a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announces the launch of the CLEAR Study in collaboration with UCLA, an innovative program to help patients suffering from Chronic Obstructive Pulmonary Disease (COPD).
-
Lubiprostone Meets Primary Endpoint In Phase 3 Clinical Trial For Opioid-Induced Bowel Dysfunction (OBD)
2/3/2012
Sucampo Pharmaceuticals, Inc. (SPI) and Takeda Pharmaceuticals U.S.A., Inc. announced recently that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
-
Ampio Pharmaceuticals, Inc. Announces Statistically Significant Improvement In Pain Relief For Its Lead Product, Ampion In The Osteoarthritis Of The Knee Trial
2/1/2012
Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced preliminary results of the pain score portion of the expansion phase of Ampion™ in Knee (AIK) trial which was recently completed in Australia.
This website uses cookies to ensure you get the best experience on our website. Learn more